MPP reached an agreement to produce Pfizer’s low-cost Paxlovid drug

Medicines Patent Pool (MPP), based in Geneva (Switzerland) has signed an agreement with 35 pharmaceutical companies around the world to produce Paxlovid drug Pfizer’s low-cost COVID-19 treatment for 95 low- and middle-income countries.

Last November, Pfizer reached an agreement with MPP that allows many pharmaceutical companies to produce generic versions of Paxlovid for 95 countries, accounting for 53% of the world’s population. Generic drugs are copies of brand-name drugs with similar active ingredients.

According to MPP, generic drug manufacturers have reached agreements to operate in 12 countries, including Vietnam. Under the agreement, the companies will produce Paxlovid or the active ingredients.

Pfizer will not receive royalties from Paxlovid’s generic drug sales while COVID-19 remains classified as a “global emergency” by WHO. After the pandemic, the company will maintain royalty-free for low-collecting countries, but charge a royalty of 5% of sales to the public sector and 10% of sales to the private sector in income countries. medium.

* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!